Institution
Cardiovascular Institute of the South
Other•Houma, Louisiana, United States•
About: Cardiovascular Institute of the South is a other organization based out in Houma, Louisiana, United States. It is known for research contribution in the topics: Myocardial infarction & Population. The organization has 6744 authors who have published 6131 publications receiving 175736 citations.
Topics: Myocardial infarction, Population, Heart failure, Coronary artery disease, Percutaneous coronary intervention
Papers published on a yearly basis
Papers
More filters
••
TL;DR: AS progressed in 41% of a selected group of patients who underwent repeated cardiac catheterization, and there were no significant differences between the 2 groups in age, interval between studies, cardiac output, left ventricular end-diastolic pressure and origin of AS.
Abstract: Factors related to progression of nonrheumatic aortic stenosis (AS) were analyzed in 29 adult patients who underwent serial hemodynamic studies over a mean of 71 months. AS was congenital in 8 patients and degenerative in 21. The patients were divided into 2 groups on the basis of the change in aortic valve area between the 2 studies. Twelve patients had a ≥ 25% reduction in aortic valve area (Group I) and 17 patients had
56 citations
••
TL;DR: Preliminary evidence is offered that patients receiving a new PCI procedure for ISR may benefit from long-term administration of aspirin plus clopidogrel.
56 citations
••
TL;DR: The purposeful transition of cell immobilization from a cytoprotection point of view to that of a cell‐instructive approach is examined, with advances in the understanding of cell–material interactions in a 3D context.
Abstract: The primary aim in tissue engineering is to repair, replace, and regenerate dysfunctional tissues to restore homeostasis. Cell delivery for repair and regeneration is gaining impetus with our understanding of constructing tissue-like environments. However, the perpetual challenge is to identify innovative materials or re-engineer natural materials to model cell-specific tissue-like 3D modules, which can seamlessly integrate and restore functions of the target organ. To devise an optimal functional microenvironment, it is essential to define how simple is complex enough to trigger tissue regeneration or restore cellular function. Here, the purposeful transition of cell immobilization from a cytoprotection point of view to that of a cell-instructive approach is examined, with advances in the understanding of cell-material interactions in a 3D context, and with a view to further application of the knowledge for the development of newer and complex hierarchical tissue assemblies for better examination of cell behavior and offering customized cell-based therapies for tissue engineering.
56 citations
••
TL;DR: Recent developments in iPSC research on regenerating injured heart tissue are reviewed, including novel advances in cell therapy and potential strategies to overcome current obstacles in the field.
56 citations
••
TL;DR: DAPT for ≤6 months is reasonable for patients treated with everolimus-eluting and fast-release zotarolimus -eluting stents, with the benefit of less major bleeding at the cost of increased MI, with similar survival and ST rates.
Abstract: The purpose of the study was to evaluate the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention, especially in the era of second-generation drug-eluting stents (DES). The work was conducted from November 2014 to April 2015. All randomized controlled trials comparing short (<12 months) versus long (≥12 months) DAPT in patients treated with second-generation DES were analyzed. Sensitivity analyses were performed for length of DAPT and type of DES. All-cause death was the primary end point, whereas cardiovascular death, myocardial infarction (MI), stent thrombosis (ST), and major bleeding were secondary end points. Results were pooled and compared with random-effect models and meta-regression analysis. Eight randomized controlled trials with 18,810 randomized patients were included. The studies compared 3 versus 12 months of DAPT (2 trials), 6 versus 12 months (3 trials), 6 versus 24 months (1 trial), 12 versus 24 months (1 trial), and 12 versus 30 months (1 trial). Comparing short versus long DAPT, there were no significant differences in all-cause death (odds ratio [OR] 0.87; 95% confidence interval [CI] 0.66 to 1.44), cardiovascular death (OR 0.95; 95% CI 0.65 to 1.37), and ST (OR 1.20; 95% CI 0.79 to 1.83), and no differences were present when considering everolimus-eluting and fast-release zotarolimus-eluting stents separately. Shorter DAPT was inferior to longer DAPT in preventing MI (OR 1.35; 95% CI 1.03 to 1.77). Conversely, major bleeding was reduced by shorter DAPT (OR 0.60; 95% CI 0.42 to 0.96). Baseline features did not influence these results in meta-regression analysis. In conclusion, DAPT for ≤6 months is reasonable for patients treated with everolimus-eluting and fast-release zotarolimus-eluting stents, with the benefit of less major bleeding at the cost of increased MI, with similar survival and ST rates. An individualized patient approach to DAPT duration should take into account the competing risks of bleeding and ischemic complications after present-generation DES.
56 citations
Authors
Showing all 6768 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eric J. Topol | 193 | 1373 | 151025 |
Peter W.F. Wilson | 181 | 680 | 139852 |
Aaron R. Folsom | 181 | 1118 | 134044 |
Valentin Fuster | 179 | 1462 | 185164 |
Ramachandran S. Vasan | 172 | 1100 | 138108 |
Michael Snyder | 169 | 840 | 130225 |
Daniel J. Rader | 155 | 1026 | 107408 |
Ronald W. Davis | 155 | 644 | 151276 |
Michael A. Matthay | 151 | 998 | 98687 |
Robert O. Bonow | 149 | 808 | 114836 |
Roxana Mehran | 141 | 1378 | 99398 |
Jonathan L. Halperin | 133 | 486 | 121655 |
Gerald M. Reaven | 133 | 799 | 80351 |
Roberto Ferrari | 133 | 1654 | 103824 |
Gregg W. Stone | 132 | 1299 | 65531 |